Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrrolidine SCHEMBL5729003 | 0.92 | HTR2C (0.40) | HTR2COXTRMAOBMAOANISCH | |
| Piperidine SCHEMBL8124922 | 0.90 | HTR2C (0.39) | HTR2COXTRMAOBMAOANISCH | |
| Azepane SCHEMBL8131041 | 0.90 | HTR2C (0.39) | HTR2COXTRMAOBMAOANISCH | |
| SCHEMBL8710 | 0.89 | — | — | |
| SCHEMBL6093132 | 0.89 | — | — | |
| SCHEMBL29386319 | 0.89 | — | — | |
| SCHEMBL730025 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL3205764 | 0.87 | MAOA (0.42) | OXTRMAOBMAOANISCHGAA | |
| SCHEMBL3682309 | 0.87 | MAOA (0.42) | OXTRMAOBMAOANISCHGAA | |
| Hydrochloric Acid SCHEMBL6762162 | 0.87 | MAOA (0.42) | OXTRMAOBMAOANISCHGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103380122-B | Novel benzodioxole piperazine compounds | HOFFMANN LA ROCHE | 2015-04-29 | — | — | CN | disclosed |
| US-8722683-B2 | Benzodioxole piperazine compounds | HOFFMANN LA-ROCHE INC. (US) | 2014-05-13 | — | — | US | disclosed |
| CN-103380122-A | Novel benzodioxole piperazine compounds | HOFFMANN LA ROCHE | 2013-10-30 | — | — | CN | disclosed |
| US-7297699-B2 | For treatment of diseases of the central nervous system, caused by disturbances of the dopaminergic and/or serotonergic and/or noradrenergic systems, for example: addiction (including craving), anxiety disorders, autism, schizophrenia | SOLVAY PHARMACEUTICALS, INC. (NL) | 2007-11-20 | — | — | US | disclosed |
| US-20060089366-A1 | New piperazine and piperidine compounds | SOLVAY PHARMACEUTICALS B.V. | 2006-04-27 | — | — | US | disclosed |
| US-6911448-B2 | Piperazine and piperidine compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-06-28 | — | — | US | disclosed |
| US-6780864-B1 | PARTIAL DOPAMINE D2-RECEPTOR AGONISM AND PARTIAL SEROTONIN 5-HT1A- RECEPTOR AGONISM MEDIATED ACTIVITIES, AFFINITY FOR ADRENERGIC ALPHA 1-RECEPTORS IS PRESENT | DUPHAR INTERNATIONAL RESEARCH BV (NL) | 2004-08-24 | — | — | US | disclosed |
| EP-1131308-B1 | NEW PIPERAZINE AND PIPERIDINE COMPOUNDS | DUPHAR INT RES (NL) | 2004-05-19 | — | — | EP | disclosed |
| EP-1283838-B1 | PIPERAZINE AND PIPERIDINE COMPOUNDS | SOLVAY PHARM BV (NL) | 2003-12-03 | — | — | EP | disclosed |
| US-20030119849-A1 | Piperazine and piperidine compounds | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-06-26 | — | — | US | disclosed |
| EP-1283838-A1 | PIPERAZINE AND PIPERIDINE COMPOUNDS | Solvay Pharmaceuticals B.V. (NL) | 2003-02-19 | — | — | EP | disclosed |
| WO-2001085725-A1 | PIPERAZINE AND PIPERIDINE COMPOUNDS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2001-11-15 | — | — | WO | disclosed |
| EP-1131308-A1 | NEW PIPERAZINE AND PIPERIDINE COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000029397-A1 | NEW PIPERAZINE AND PIPERIDINE COMPOUNDS | DUPHAR INTERNATIONAL RESEARCH BV (NL) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089366-A1 | New piperazine and piperidine compounds | HTR3C, HTR3A, ADRB3 | HTR2C 9/4885OXTR 162/4885MAOB 152/4885 |
| US-20030119849-A1 | Piperazine and piperidine compounds | HTR3C, OPRD1, OPRL1 | HTR2C 5/4885OXTR 175/4885MAOB 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.